The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer.
The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer.
复制标题
可切除非小细胞肺癌新辅助免疫治疗的外科前景。
DOI：
10.1007/s00262-021-02847-1
复制
发表时间：
2021-08
期刊：
影响因子：
--
通讯作者：
Luo Q
中科院分区：
文献类型：
--
作者：
Jiang L;Huang J;Jiang S;Rong W;Shen Y;Li C;Tian Y;Ning J;Chen X;Yang Y;Ding Z;Li Z;Luo Q
新辅助免疫治疗的新概念引起了全世界外科医生的兴趣，特别是缺乏新辅助免疫治疗人群的手术治疗经验。回顾性收集了2018年9月至2020年4月期间接受新辅助免疫治疗或化学免疫治疗的非小细胞肺癌（NSCLC）患者。通过回顾性图表分析收集所有个体的人口统计学数据、病理和临床特征、治疗方案和结局数据。手术细节，新辅助治疗的信息，也被提取。最终分析共纳入31例患者。患者的中位年龄为61岁。共有29例患者为男性，2例为女性。患者在切除前接受了中位3次剂量。从最终治疗到手术的中位持续时间为34天。新辅助治疗后，治疗后计算机断层扫描显示24例患者部分缓解。总共有12/31例患者出现主要病理学缓解，15例病理学分期下调。3例患者无残留存活肿瘤。7例手术切缘阳性。所有31例患者中有18例发生了一种或多种术后并发症。总共有26名患者在手术前接受了下一代测序。其中2例患者检测到STK 11突变，最终病理检查均无重大病理反应。在当前人群中，新辅助免疫治疗或化学免疫治疗可切除NSCLC后行肺切除术似乎是安全的，手术死亡率和发病率较低。
The recent novel conception of neoadjuvant immunotherapy has generated interest among surgeons worldwide, especially the lack of experience involving surgical treatment for the neoadjuvant immunotherapy population. Patients with non-small cell lung cancer (NSCLC), who underwent neoadjuvant immunotherapy or chemo-immunotherapy, were retrospectively collected between September 2018 and April 2020. Demographic data, pathological and clinical features, therapeutic regimens and outcome data of all individuals were collected by retrospective chart review. Operative details, information of neoadjuvant therapy, were also abstracted. In total, 31 patients were included in the final analysis. The patients’ median age was 61 years. In total, 29 of the patients were males, while 2 were females. Patients received a median of 3 doses before resection. The median duration from final treatment to surgery was 34 days. After neoadjuvant treatment, post-treatment computed tomography scan showed that 24 patients had partial response. In total, 12 of 31 patients had a major pathological response, 15 pathological downstaging. Three patients had no residual viable tumor. A positive surgical margin was identified in 7 cases. One or more postoperative complications occurred in 18 of all 31 patients. In total, 26 patients underwent next-generation sequencing before surgery in total. Among them, 2 patients were detected STK11 mutations, none of whom had a major pathological response by final pathological examination. Pulmonary resection after neoadjuvant immunotherapy or chemo-immunotherapy for resectable NSCLC appears to be safe with low operative mortality and morbidity rate in the current population.
登录
查看更多内容
DOI：
10.1016/s1470-2045(13)70334-6
发表时间：
2014-01
期刊：
The Lancet. Oncology
影响因子：
--
作者：
Hellmann MD;Chaft JE;William WN Jr;Rusch V;Pisters KM;Kalhor N;Pataer A;Travis WD;Swisher SG;Kris MG;University of Texas MD Anderson Lung Cancer Collaborative Group
通讯作者：
University of Texas MD Anderson Lung Cancer Collaborative Group
影响因子：
20.4
作者：
Goldstraw, Peter;Chansky, Kari;Bolejack, Vanessa
通讯作者：
Bolejack, Vanessa
影响因子：
20.4
作者：
Gao, Shugeng;Li, Ning;He, Jie
通讯作者：
He, Jie
DOI：
10.6004/jnccn.2019.0059
发表时间：
2019-12-01
影响因子：
13.4
作者：
Ettinger, David S.;Wood, Douglas E.;Hughes, Miranda
通讯作者：
Hughes, Miranda
影响因子：
120.7
作者：
Pan, An;Liu, Li;Wu, Tangchun
通讯作者：
Wu, Tangchun